Compare Rush Street Interactive Inc (RSI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs Sanofi SA — how do they compare? Rush Street Interactive Inc trades at $24.24 (market cap $2.91B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 35.8× Rush Street Interactive Inc's market cap, and Sanofi SA pays a 5.55% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals.
| RSI | SNY | |
|---|---|---|
Market Cap | $2.91B | $104.30B |
Sector | Technology | Health |
52-Week High | $34.52 | $52.34 |
52-Week Low | $15.89 | $41.33 |
Enterprise Value | $2.57B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rush Street Interactive (RSI) trades at $24.53, down 0.77% on the day, amid mixed technical signals with a bearish overall trend but oversold oscillators. The company reported strong Q2 2026 results with record revenue of $393.8 million and raised full-year guidance, though net margins remain thin at 2.33%. Analyst sentiment remains bullish with 77% buy ratings and a $34.75 consensus target.
RSI shows promising revenue growth and institutional interest but faces valuation concerns with a high P/E of 81.13. The stock offers significant upside to analyst targets but requires careful monitoring of margin expansion and competitive pressures in the online gambling sector.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
